Brandy Lind

Executive Director, Project Management

Brandy Lind

Executive Director, Project Management

A true leader within the Project Management department at Rho for more than 15 years, Brandy Lind has focused her research in asthma and allergic diseases.

Her career began in the NIAID/NIH-funded Inner City Asthma Consortium (ICAC), where Ms. Lind supported clinical trials in anti-IgE therapy and exhaled nitric oxide tests. This research she helped conduct under ICAC proved pivotal and was influential in changing the national asthma guidelines. She also served as a Program Director for the NIAID/NIH-funded Immune Tolerance Network (ITN) Statistical and Data Coordinating Center, during which the ITN had over 30 studies in the areas of allergy, immunology, and transplantation.

Another notable project during Ms. Lind’s tenure was the landmark LEAP, or the Learning Early About Peanut Allergy, study which demonstrated that regular peanut consumption (beginning in infancy and continuing through 5 years of age) led to an 81% reduction in the development of peanut allergy in high-risk children.

In her roles, she ensured that clinical trials met enrollment and study timelines, quality standards and regulations, as well as overall budget. She oversaw the hiring and training of the entire team and was responsible for resource allocation across clinical trials. And Ms. Lind also has experience working with many common pulmonary function tests such as spirometry, methacholine challenge, exhaled nitric oxide, and lung volume.

A seasoned project manager with a track record of building effective project teams and successfully executing trials, Ms. Lind has successfully led a variety of Phase I-III clinical trials and complex global programs throughout her career.

Why respiratory?

“When I first started at Rho, I was fortunate to be assigned to the Inner City Asthma Consortium (ICAC), a research consortium that had been working together since 1991. Over the next 5 years, I learned how asthma and allergic disease severely impacts children, especially those living in inner cities. It was an eye-opening experience to travel to the sites and hear the patients talk about how asthma has affected their child’s attendance at school, caused numerous ED visits, and left them with high healthcare bills. This research became important to me because I knew that reducing the number of asthma exacerbations could make a real difference in the lives of these children and their families.”

This is what drives Brandy:

“I want to help patients improve their quality of life, and this drives me to build effective teams and efficient processes so that we can deliver quality results as quickly as possible.”

Content by Brandy Lind


Strategies to Avoid Enrollment Delays

Completing enrollment is typically one of the most critical milestones in a clinical trial. Enrollment delays impact the study budget, site resources, and downstream timelines. Therefore, it is important to identify potential risks to enrollment early in the study, even during the protocol development process if possible. Defining risk mitigation strategies and setting quality tolerance limits allows the study team to quickly identify when a strategy must be implemented to keep enrollment on track. In this webinar, we will discuss how we have used a risk-based quality management system to document enrollment risks and creative solutions we have implemented.

Brandy Lind
Blog Post

Beating the Odds: 5 Strategies to Improve Clinical Trial Enrollment

Hitting the clinical trial enrollment goal is not only important to meeting overall study timelines and budgets, it is critical to the success of the clinical study.  If you don’t have enough participants, you won’t have enough data to support your objectives. That’s why it’s important to plan for enrollment just as you would plan for collecting and analyzing the data.